glucose | 4.34 g/L | AFP | 4.2 ng/ml |
T-BIL | 14.0 μmol/L | CA724 | 0.9 U/ml |
GGT | 420 g/L | CYRA21–1 | 2.1 ng/ml |
ALT | 92 μmol/L | WBC | 8.46 × 109 /L |
AST | 60 μmol/L | Neu | 68.3% |
BUN | 4.51 g/L | Lym | 8.0% |
SCr | 59 g/L | EOS | 17.4% |
CRP | 114.84 mg/L | Hb | 124 g/L |
PCT | 1.840 ng/ml | MCV | 84.6 fl |
HIV-Ab | (−) | PLT | 300 × 109 /L |
SCC | 0.4 ng/mL | Serum G assay | (−) |
NSE | 22.1 ng/ml | Serum GM assay | (−) |
Pro-GRP | 28.3 pg/mL | T-spot | (−) |
CEA | 0.9 U/ml | Total IgE | >2500.00 KIU/L |
CA125 | 41.6 U/ml | BAL-G assay | (+) |
CA199 | 12.5 U/ml | BAL-GM assay | (−) |
- T-BIL Total- bilirubin, GGT gamma-glutamyl transpeptidase, ALT alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, SCr serum creatinine, CRP=C-reactive protein, PCT procalcitonin, SCC squamous cell carcinoma antigen, NSE neuron specific endase, pro-GRP Human pro-gastrin-reliasing peptide, CEA carcinoembryonic antigen, CA125 carbohydrate antigen 125, CA199 carbohydrate antigen 199, AFP alpha fetoprotein, CA724 carbohydrate antigen 724, CYRA21–1 cytokeratin 19 fragment, WBC white blood cell count, Neu neutrophil count, Lym lymphocyte count, EOS eosnophils, Hb hemoglobin, MCV Mean Corpuscular Volume, PLT platelets, G assay (1/3) -b-D-glucan assay; GM assay galactomannan antigen assay
